 Prognostic factors aggressive malignant lymphomas description validation prognostic index patients intensive therapy Groupe d'Etudes des Lymphomes Agressifs objectives study prognostic factors response treatment freedom-from-relapse FFR survival overall survival aggressive malignant lymphoma patients doxorubicin cyclophosphamide vindesine bleomycin methylprednisolone methotrexate leucovorin ifosfamide asparaginase cytarabine regimen prognostic index factors multivariate analyses prognostic index set patients Complete response CR patients median follow-up months median FFR survival median overall survival Low serum albumin level high tumoral mass weight loss bone marrow involvement equal extranodal sites lactic dehydrogenase LDH level low response rate Advanced stage LDH level nonlarge-cell histologic subtypes mixed lymphoblastic small non-cleaved high relapse rate short FFR survival LDH level low serum albumin level tumoral mass cm equal extranodal sites advanced stage age years short overall survival parameters LDH level stage number extranodal sites tumoral mass prognostic index index patients subgroups good intermediate poor prognosis CR rates relapse rates FFR survival survival prognostic index test set patients patients protocols Nebraska Lymphoma Study Group index patients FFR survival survival patients aggressive lymphomas simple prognostic index patients intensive treatment autologous bone marrow transplantation first complete remission standard regimens